⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29068210 | 0.83 | NPC1 (0.35) | — | |
| SCHEMBL8603815 | 0.78 | PNP (0.34) | — | |
| SCHEMBL14424070 | 0.78 | MEN1 (0.38) | — | |
| SCHEMBL5988807 | 0.74 | GABRA1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL20958707 | 0.71 | CHRNB2 (0.32) | — | |
| SCHEMBL312460 | 0.70 | — | — | |
| SCHEMBL17572657 | 0.69 | LYN (0.54) | — | |
| SCHEMBL5751212 | 0.69 | CYP1A2 (0.45) | — | |
| SCHEMBL22002706 | 0.68 | NPC1 (0.34) | — | |
| SCHEMBL16518823 | 0.67 | NPC1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964196-A | Recombinant oncolytic virus and medical application thereof | 深圳艾欣达伟医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11129829-B2 | Methods for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11021708-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019012001-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1458726-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1551812-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |